πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 763 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10272099

Tumor-selective combination therapy

The Board of Regents of the University of Texas System Β· Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10265397

Formulation for photodynamic therapy

SANOCHEMIA PHARMAZEUTIKA AG Β· Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10265412

Enzyme replacement therapy for treating lysosomal storage diseases

The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center Β· Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10258678

Indoleamine 2,3-dioxygenase based immunotherapy

IO Biotech ApS Β· Granted Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10231958

Methods and compositions for enhancing chemotherapy

The Board of Regents of the University of Texas System Β· Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10221455

Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VI

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10221244

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. Β· Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10195297

Iron garnet nanoparticles for cancer radiotherapy and chemotherapy

The Board of Regents of the University of Texas System Β· Granted Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10188751

Papillomavirus pseudoviruses for detection and therapy of tumors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10179112

Viral vector nanocapsule for targeting gene therapy and its preparation

The Regents of the University of California Β· Granted Tue Jan 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10172836

Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation supression ther

PTC THERAPEUTICS, INC. Β· Granted Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10166277

Vault immunotherapy

THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS Β· Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10166257

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10167337

Combination immunotherapy for the treatment of cancer

The Board of Regents of the University of Texas System Β· Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10166255

Intracellular genomic transplant and methods of therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10159727

Compositions and methods for combination therapy with dengue virus and dendritic cells

PrimeVax Immuno-Oncology Β· Granted Tue Dec 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10154970

Methods for immunomodulation of cancer and infectious disease therapy

The Regents of the University of California Β· Granted Tue Dec 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10143751

Photodynamic therapy, formulation usable for this purpose, and method for the production a

SANOCHEMIA PHARMAZEUTIKA AG Β· Granted Tue Dec 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10137104

Combination therapy with an anti-hyaluronan agent and therapeutic agent

HALOZYME, INC. Β· Granted Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10130651

RNAi Therapy for Hepatitis B Virus Infection

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10130658

Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a smal

Provectus Pharmatech, Inc. Β· Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10130659

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10117915

Modulation of yeast-based immunotherapy products and responses

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10087232

Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy

Protalix Ltd. Β· Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted